

Unless otherwise defined herein, the capitalised defined terms used in this announcement have the same meaning as those used in the Company's announcements released on 27 June 2023 unless otherwise defined herein.

29 June 2023

Physiomics plc
(**"PYC"** or the **"Company"**)

Completion of Fundraise to raise gross proceeds of £380,477

Physiomics plc (AIM:PYC) is pleased to announce, further to its announcements of 27 June 2023, the completion of the Subscription and the WRAP Retail Offer, as well as the placing of an additional 2,000,000 Ordinary Shares on the same terms as the Placing (together, the **"Fundraise"**). The Fundraise, which is conditional on Admission, raises gross proceeds of, in aggregate, £380,477 through the issue of a total of 38,047,700 new Ordinary Shares (the **"Fundraise Shares"**).

Enlarged Placing

Further to the Company's announcement of 27 June 2023, the Company is pleased to confirm that it has placed an additional 2,000,000 new Ordinary Shares on the same terms as the Placing, through Hybridan LLP, taking the total placing to 34,500,000 new Ordinary Shares raising gross proceeds of, in aggregate, £345,000.

WRAP Retail Offer

The WRAP Retail Offer, which closed at 16:30 BST yesterday, has raised gross proceeds of £25,477 through the issue of 2,547,700 new Ordinary Shares to existing retail shareholders in the United Kingdom.

Director Subscriptions

Further to the Company's announcement of 27 June 2023, the Company can confirm that Dr James ('Jim') Millen (Executive Chairman and CEO) and Dr Christophe Chassagnole (COO) have each subscribed for £5,000 of new Ordinary Shares at the Placing price pursuant to a direct subscription with the Company and accordingly will each be issued 500,000 new Ordinary Shares. On Admission, Dr Millen and Dr Chassagnole will be interested in, in aggregate, 1,884,393 and 1,102,723 Ordinary Shares respectively, representing 1.39% and 0.81% of the Company's then enlarged issued share capital.

Use of Proceeds

In order to further develop its business and accelerate growth, the Company targeted a raise of around £300,000 with the intention of using the net proceeds of the Fundraise towards activities including:

- Further expansion and diversification of its client base;
- Expansion of its consulting business into the adjacent area of pharmaceutical biostatistics services; and
- Exploration of opportunities around its personalised oncology software offering.

Admission and Total Voting Rights

Application has been made for the 38,047,700 Fundraise Shares to be admitted to trading on AIM, which is expected to take effect and dealings to commence at 8.00 a.m. on or around 3 July 2023 ("Admission").

Following Admission, the Company will have 135,472,478 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will therefore be 135,472,478. These figures may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance

James Bellman

+44 (0)20 7409 3494

Winterflood Retail Access Platform

Alex Skrine, Head of Electronic Trading

Haris Khawaja, Corporate Finance

WRAP@winterflood.com

+44 (0) 20 3100 0009

+44 (0) 20 3100 0189

The Company's LEI is 213800A71DSZ6ABMTQ91

PDMR Notification Forms

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Jim Millen
2.	Reason for the Notification	
a)	Position/status	Executive Chairman and CEO
b)	Initial notification/amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	

a)	Name	Physiomics plc	
b)	LEI	213800A71DSZ6ABMTQ91	
4.	Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted		
a)	Description of the Financial instrument, type of instrument	Physiomics plc new Ordinary Shares	
	Identification code	ISIN: GB00BDR6W943	
b)	Nature of the Transaction	A subscription for new ordinary shares in the Company	
c)	Price(s) and volume(s)	Dr Jim Millen	
		Price(s)	Volume(s)
		£0.01	500,000
d)	Aggregated information		
	- Aggregated volume	500,000	
	- Price	£0.01	
e)	Date of the transaction	28 June 2023	
f)	Place of the transaction	Off market transaction	

1.	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Christophe Chassagnole
2.	Reason for the Notification	
a)	Position/status	Executive Director, COO
b)	Initial notification/amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Physiomics plc
b)	LEI	213800A71DSZ6ABMTQ91
4.	Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted	
a)	Description of the Financial instrument, type of instrument	Physiomics plc new Ordinary Shares
	Identification code	ISIN: GB00BDR6W943
b)	Nature of the Transaction	A subscription for new ordinary shares in the Company

c)	Price(s) and volume(s)	Dr Christophe Chassagnole	
		Price(s)	Volume(s)
		£0.01	500,000
d)	Aggregated information		
	- Aggregated volume	500,000	
	- Price	£0.01	
e)	Date of the transaction	28 June 2023	
f)	Place of the transaction	Off market transaction	

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019.